Pfizer (PFE) Tops Q1 EPS by 12c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
PFIZER REPORTS FIRST-QUARTER 2016 RESULTS
May 3, 2016 6:45 AM EDTFirst-Quarter 2016 Reported Revenues(1) of $13.0 Billion, Reflecting 26% Operational Growth Driven by 28% Operational Growth from the Innovative Products Business and the Inclusion of Legacy Hospira Operations First-Quarter 2016 Reported Revenues(1) for Pfizer Standalone (Excluding Legacy Hospira) of $11.8 Billion, Reflecting 15% Operational Growth First-Quarter 2016 Adjusted Diluted EPS(2) of $0.67, Reported Diluted EPS(1) of $0.49 Raised Midpoint of 2016 Financial Guidance Ranges for Reported Revenues(1) by $2.0 Billion and Adjusted Diluted EPS(2) by $0.18, Reflecting Strong Performance to Date and Improved Outlook for 2016 as well as Favorable Impact of Recent Changes in Foreign Exchange Rates... More
